These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 31629542)

  • 1. Overexpression of somatostatin receptor type 2 in neuroendocrine tumors for improved Ga68-DOTATATE imaging and treatment.
    Guenter R; Aweda T; Carmona Matos DM; Jang S; Whitt J; Cheng YQ; Liu XM; Chen H; Lapi SE; Jaskula-Sztul R
    Surgery; 2020 Jan; 167(1):189-196. PubMed ID: 31629542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation and Comparison of Somatostatin Receptor Type 2 Immunohistochemical Scoring Systems with 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms.
    Yu J; Cao F; Zhao X; Xie Q; Lu M; Li J; Yang Z; Sun Y
    Neuroendocrinology; 2022; 112(4):358-369. PubMed ID: 34077939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing Somatostatin Receptor Imaging in Patients With Neuroendocrine Tumors: The Impact of 99mTc-HYNICTOC SPECT/SPECT/CT Versus 68Ga-DOTATATE PET/CT Upon Clinical Management.
    Kunikowska J; Lewington V; Krolicki L
    Clin Nucl Med; 2017 Dec; 42(12):905-911. PubMed ID: 29076910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatocellular Carcinoma Mimicking Neuroendocrine Tumor Metastasis on 68Ga-DOTATATE PET/CT.
    Ulaner GA; Bodei L
    Clin Nucl Med; 2019 Apr; 44(4):330-331. PubMed ID: 30688738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice.
    Aalbersberg EA; Geluk-Jonker MM; Young-Mylvaganan T; de Wit-van der Veen LJ; Stokkel MPM
    J Vis Exp; 2019 Apr; (146):. PubMed ID: 31058910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant.
    Pivonello R; Munster PN; Terzolo M; Ferrigno R; Simeoli C; Puglisi S; Bali U; Moraitis AG
    Front Endocrinol (Lausanne); 2021; 12():793262. PubMed ID: 35058882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential for Increasing Uptake of Radiolabeled
    Pollard JH; Menda Y; Zamba KD; Madsen M; O'Dorisio MS; O'Dorisio T; Bushnell D
    Cancer Biother Radiopharm; 2021 Oct; 36(8):632-641. PubMed ID: 34252288
    [No Abstract]   [Full Text] [Related]  

  • 8. Head-to-Head Comparison of
    Zhu W; Cheng Y; Wang X; Yao S; Bai C; Zhao H; Jia R; Xu J; Huo L
    J Nucl Med; 2020 Jun; 61(6):897-903. PubMed ID: 31676731
    [No Abstract]   [Full Text] [Related]  

  • 9. Defining the optimal segmentation method for measuring somatostatin receptor expressing tumor volume on 68 Ga-DOTATATE positron emission tomography/computed tomography to predict prognosis in patients with gastroenteropancreatic neuroendocrine tumors.
    Filizoglu N; Ozguven S; Akin Telli T; Ones T; Dede F; Turoglu HT; Erdil TY
    Nucl Med Commun; 2024 Aug; 45(8):736-744. PubMed ID: 38745508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastro-Entero-Pancreatic Tumors: FDG Positron Emission Tomography/Computed Tomography.
    Khatri W; Spiro E; Henderson A; Rowe SP; Solnes LB
    PET Clin; 2023 Apr; 18(2):243-250. PubMed ID: 36707371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of initial imaging with gallium-68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors.
    Crown A; Rocha FG; Raghu P; Lin B; Funk G; Alseidi A; Hubka M; Rosales J; Lee M; Kennecke H
    J Surg Oncol; 2020 Mar; 121(3):480-485. PubMed ID: 31853990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
    Jois B; Asopa R; Basu S
    Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Prospective Observational Study to Evaluate the Effects of Long-Acting Somatostatin Analogs on
    Gålne A; Almquist H; Almquist M; Hindorf C; Ohlsson T; Nordenström E; Sundlöv A; Trägårdh E
    J Nucl Med; 2019 Dec; 60(12):1717-1723. PubMed ID: 31000584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The utility of
    Tirosh A; Kebebew E
    Future Oncol; 2018 Jan; 14(2):111-122. PubMed ID: 29072093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 68Ga-DOTATATE Uptake in Pancreatic Metastasis of Renal Cell Carcinoma Mimicking Pancreatic Neuroendocrine Tumor.
    Soydal C; Nak D; Araz M; Demirkazik A; Kucuk NO
    Clin Nucl Med; 2019 Oct; 44(10):795-796. PubMed ID: 31306201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gallium-68-dotatate PET/CT is better than CT in the management of somatostatin expressing tumors: First experience in Africa.
    Lawal IO; Ololade KO; Lengana T; Reyneke F; Ankrah AO; Ebenhan T; Vorster M; Sathekge MM
    Hell J Nucl Med; 2017; 20(2):128-133. PubMed ID: 28697189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroendocrine Tumors: Diagnostics.
    Sakellis C; Jacene HA
    PET Clin; 2024 Jul; 19(3):325-339. PubMed ID: 38714399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.
    Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
    Recent Results Cancer Res; 2013; 194():353-71. PubMed ID: 22918768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-to-Blood Ratio for Assessment of Somatostatin Receptor Density in Neuroendocrine Tumors Using
    Ilan E; Velikyan I; Sandström M; Sundin A; Lubberink M
    J Nucl Med; 2020 Feb; 61(2):217-221. PubMed ID: 31302632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.